PMC:7283670 / 97179-99249 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T788","span":{"begin":295,"end":300},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T789","span":{"begin":314,"end":315},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T790","span":{"begin":405,"end":407},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T791","span":{"begin":443,"end":444},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T792","span":{"begin":735,"end":740},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T793","span":{"begin":754,"end":755},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T794","span":{"begin":907,"end":913},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T795","span":{"begin":932,"end":933},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T796","span":{"begin":1199,"end":1204},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T797","span":{"begin":1218,"end":1219},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020"}

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T843","span":{"begin":0,"end":461},"obj":"Sentence"},{"id":"T844","span":{"begin":462,"end":527},"obj":"Sentence"},{"id":"T845","span":{"begin":528,"end":652},"obj":"Sentence"},{"id":"T846","span":{"begin":653,"end":722},"obj":"Sentence"},{"id":"T847","span":{"begin":723,"end":762},"obj":"Sentence"},{"id":"T848","span":{"begin":763,"end":886},"obj":"Sentence"},{"id":"T849","span":{"begin":887,"end":906},"obj":"Sentence"},{"id":"T850","span":{"begin":907,"end":948},"obj":"Sentence"},{"id":"T851","span":{"begin":949,"end":985},"obj":"Sentence"},{"id":"T852","span":{"begin":986,"end":1180},"obj":"Sentence"},{"id":"T853","span":{"begin":1181,"end":1225},"obj":"Sentence"},{"id":"T854","span":{"begin":1226,"end":1421},"obj":"Sentence"},{"id":"T855","span":{"begin":1422,"end":1463},"obj":"Sentence"},{"id":"T856","span":{"begin":1464,"end":1520},"obj":"Sentence"},{"id":"T857","span":{"begin":1521,"end":2070},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020"}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T274","span":{"begin":177,"end":186},"obj":"Phenotype"},{"id":"T275","span":{"begin":375,"end":384},"obj":"Phenotype"},{"id":"T276","span":{"begin":579,"end":588},"obj":"Phenotype"},{"id":"T277","span":{"begin":814,"end":823},"obj":"Phenotype"},{"id":"T278","span":{"begin":1037,"end":1046},"obj":"Phenotype"},{"id":"T279","span":{"begin":1277,"end":1286},"obj":"Phenotype"},{"id":"T280","span":{"begin":1664,"end":1669},"obj":"Phenotype"}],"attributes":[{"id":"A274","pred":"hp_id","subj":"T274","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A275","pred":"hp_id","subj":"T275","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A276","pred":"hp_id","subj":"T276","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A277","pred":"hp_id","subj":"T277","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A278","pred":"hp_id","subj":"T278","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A279","pred":"hp_id","subj":"T279","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A280","pred":"hp_id","subj":"T280","obj":"http://purl.obolibrary.org/obo/HP_0012735"}],"text":"Evaluating the efficacy and safety of bromhexine hydrochloride tablets combined with standard treatment/standard treatment in patients with suspected and mild novel coronavirus pneumonia (COVID‐19) Drug: bromhexine hydrochloride tablets, drug: arbidol hydrochloride granules, drug: recombinant human interferon α2b spray, drug: favipiravir tablets China, novel coronavirus pneumonia 2019‐nCoV 60, all, 18–80 Treatment Experimental: group A treatment group:\nBromhexine hydrochloride tablets, arbidol hydrochloride granules:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. Arbidol hydrochloride granules is recommended but not enforced to use\nRecombinant human interferon α2b spray:\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection\nFavipiravir tablets\nActive comparator; group B control group:\nDrug: arbidol hydrochloride granules\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection. arbidol hydrochloride granules is recommended but not enforced to use\nDrug: recombinant human interferon α2b spray\nStandard treatment refers to the latest edition of pneumonia diagnosis and treatment scheme for novel coronavirus infection Not applicable Primary (within 14 days from the start of medication):\nTime to clinical recovery after treatment\nSecondary (within 14 days from the start of medication):\nRate of aggravation, clinical remission rate, dynamic changes of oxygenation index, time to cure, rate to cure, time to defervescence, time to cough remission,days of supplemental oxygenation, rate of patients with requring supplemental oxygen, rate of patients with mechanical ventilation, time of negative COVID‐19 nucleic acid results, rate of negative COVID‐19 nucleic acid results, rate of ICU admission, 28‐day mortality (From the first day of screening to the day of follow‐up (28 days)) NCT04273763/Enrolling by invitation, Feb16‐Apr30 2020"}

LitCovid-PubTator